Epitranscriptomic mC methylation of SARS-CoV-2 RNA regulates viral replication and the virulence of progeny viruses in the new infection.

Sci Adv

State Key Laboratory of Virology, Modern Virology Research Center and RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430072, China.

Published: August 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

While the significance of N6-methyladenosine (mA) in viral regulation has been extensively studied, the functions of 5-methylcytosine (mC) modification in viral biology remain largely unexplored. In this study, we demonstrate that mC is more abundant than mA in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and provide a comprehensive profile of the mC landscape of SARS-CoV-2 RNA. Knockout of NSUN2 reduces mC levels in SARS-CoV-2 virion RNA and enhances viral replication. deficiency mice exhibited higher viral burden and more severe lung tissue damages. Combined RNA-Bis-seq and mC-MeRIP-seq identified the NSUN2-dependent mC-methylated cytosines across the positive-sense genomic RNA of SARS-CoV-2, and the mutations of these cytosines enhance RNA stability. The progeny SARS-CoV-2 virions from deficiency mice with low levels of mC modification exhibited a stronger replication ability. Overall, our findings uncover the vital role played by NSUN2-mediated mC modification during SARS-CoV-2 replication and propose a host antiviral strategy via epitranscriptomic addition of mC methylation to SARS-CoV-2 RNA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305390PMC
http://dx.doi.org/10.1126/sciadv.adn9519DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 rna
12
sars-cov-2
8
methylation sars-cov-2
8
viral replication
8
deficiency mice
8
rna
6
viral
5
epitranscriptomic methylation
4
rna regulates
4
regulates viral
4

Similar Publications

Antiviral efficacy of silicon nitride against SARS-CoV-2 and MERS-CoV: implications for PPE innovation.

Front Microbiol

August 2025

Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States.

Medical interventions, such as masks, were a cornerstone in mitigating the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since 2019, the scientific community has increasingly focused on exploring avenues for pandemic prevention and preparedness to enhance responses to future viral outbreaks. One such area of interest explores the use of additives, such as silicon nitride (Si₃N₄), in masks to enhance the antiviral properties of personal protective equipment.

View Article and Find Full Text PDF

Background: The SARS-CoV-2 virus has evolved subvariants since the emergence of the omicron variant in 2021. Whether these changes impact viral shedding and transmissibility is not known.

Methods: POSITIVES is a prospective longitudinal cohort of individuals with mild SARS-CoV-2 infection.

View Article and Find Full Text PDF

The emergence of messenger ribonucleic acid (mRNA) vaccines as an alternative platform to traditional vaccines has been accompanied by advances in nanobiotechnology, which have improved the stability and delivery of these vaccines through novel nanoparticles (NPs). Specifically, the development of NPs for mRNA delivery has facilitated the loading, protection and release of mRNA in the biological microenvironment, leading to the stimulation of mRNA translation for effective intervention strategies. Intriguingly, two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), have been permitted for emergency usage authorization to prevent COVID-19 infection by USFDA.

View Article and Find Full Text PDF

Coronavirus, a large family of positive-sense RNA viruses, are responsible for both mild and severe respiratory illnesses, ranging from the common cold to life-threatening conditions. Despite significant advances in vaccine and antiviral development, the high mutability of human coronaviruses (HCoVs), such as SARS-CoV-2, presents a major challenge in treating these infections. Effective, broad-spectrum antiviral drugs are urgently needed to address both current and future HCoV outbreaks.

View Article and Find Full Text PDF